BACKGROUND: Even though bupropion is first-line pharmacological agent for smoking cessation, not all the smokers successfully quit smoking by bupropion. It means other factors like genetic predisposition could contribute to the therapeutic outcome. OBJECTIVES: The aim of this study is to elucidate the question of whether the abstinence rates by bupropion trial would be different depending on the genotypes. METHODS: Six candidate genes, thought to be involved in the interaction of nicotine and bupropion (for example, the dopamine receptor type 2, dopamine transporter, norepinephrine transporter, serotonin transporter, catecholamine-O-methyltransferase), and the clinical outcomes of smoking behavior were investigated. The participants were 225 male smokers to whom 150 mg of bupropion SR was administered for 4 weeks. The abstinence rates of specific genotypes were also compared. MAIN RESULTS: The results are as follows: (a) the frequencies of the A1/A2 genotype of the dopamine receptor type 2 TaqI A gene and SLC6A3-9 genotype of the dopamine transporter 1 gene were higher in the nonabstinence group than in the abstinence group (chi2=20.40, P<0.01 for A1/A2, chi2=7.76, P=0.01 for SLC6A3-9). The frequencies of the COMTH/COMTH and A/G genotypes of the norepinephrine transporter gene were higher in the abstinence group than in the nonabstinence group (chi2=8.12,P=0.02 for COMTH/COMTH, chi2=3.04, P<0.01 for A/G). (b) Participants having specific genotypes such as homozygotes (A1/A1 or A2/A2) of DRD2 TaqI A, COMTH/COMTH, AG of NET-8, and LL of 5-HTTLPR showed a higher abstinence rate than the other participants. CONCLUSIONS: It can be concluded that genetic diversity might determine the effects of bupropion on smoking cessation.
BACKGROUND: Even though bupropion is first-line pharmacological agent for smoking cessation, not all the smokers successfully quit smoking by bupropion. It means other factors like genetic predisposition could contribute to the therapeutic outcome. OBJECTIVES: The aim of this study is to elucidate the question of whether the abstinence rates by bupropion trial would be different depending on the genotypes. METHODS: Six candidate genes, thought to be involved in the interaction of nicotine and bupropion (for example, the dopamine receptor type 2, dopamine transporter, norepinephrine transporter, serotonin transporter, catecholamine-O-methyltransferase), and the clinical outcomes of smoking behavior were investigated. The participants were 225 male smokers to whom 150 mg of bupropion SR was administered for 4 weeks. The abstinence rates of specific genotypes were also compared. MAIN RESULTS: The results are as follows: (a) the frequencies of the A1/A2 genotype of the dopamine receptor type 2 TaqI A gene and SLC6A3-9 genotype of the dopamine transporter 1 gene were higher in the nonabstinence group than in the abstinence group (chi2=20.40, P<0.01 for A1/A2, chi2=7.76, P=0.01 for SLC6A3-9). The frequencies of the COMTH/COMTH and A/G genotypes of the norepinephrine transporter gene were higher in the abstinence group than in the nonabstinence group (chi2=8.12,P=0.02 for COMTH/COMTH, chi2=3.04, P<0.01 for A/G). (b) Participants having specific genotypes such as homozygotes (A1/A1 or A2/A2) of DRD2 TaqI A, COMTH/COMTH, AG of NET-8, and LL of 5-HTTLPR showed a higher abstinence rate than the other participants. CONCLUSIONS: It can be concluded that genetic diversity might determine the effects of bupropion on smoking cessation.
Authors: Michele L Pergadia; Arpana Agrawal; Anu Loukola; Grant W Montgomery; Ulla Broms; Scott F Saccone; Jen C Wang; Alexandre A Todorov; Kauko Heikkilä; Dixie J Statham; Anjali K Henders; Megan J Campbell; John P Rice; Richard D Todd; Andrew C Heath; Alison M Goate; Leena Peltonen; Jaakko Kaprio; Nicholas G Martin; Pamela A F Madden Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2009-10-05 Impact factor: 3.568
Authors: Meredith S Shiels; Han Yao Huang; Sandra C Hoffman; Yin Yao Shugart; Judy Hoffman Bolton; Elizabeth A Platz; Kathy J Helzlsouer; Anthony J Alberg Journal: Prev Med Date: 2008-04-01 Impact factor: 4.018
Authors: L C Bidwell; J E McGeary; J C Gray; R H C Palmer; V S Knopik; J MacKillop Journal: Pharmacol Biochem Behav Date: 2015-09-26 Impact factor: 3.533
Authors: Andrew W Bergen; David V Conti; David Van Den Berg; Wonho Lee; Jinghua Liu; Dalin Li; Nan Guo; Huaiyu Mi; Paul D Thomas; Christina N Lessov-Schlaggar; Ruth Krasnow; Yungang He; Denise Nishita; Ruhong Jiang; Jennifer B McClure; Elizabeth Tildesley; Hyman Hops; Rachel F Tyndale; Neal L Benowitz; Caryn Lerman; Gary E Swan Journal: Neuropsychopharmacology Date: 2009-06-03 Impact factor: 7.853